Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

Rhea-AI Summary

Bellerophon Therapeutics (Nasdaq: BLPH) announced that Dr. Naseem Amin, Chairman of the Board, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, taking place virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM Eastern Time on the Company’s website. Bellerophon focuses on developing innovative therapies for cardiopulmonary diseases, including products under its proprietary INOpulse® program, a nitric oxide delivery system.

News Market Reaction – BLPH

+4.85%

+4.85% News Effect

On the day this news was published, BLPH gained 4.85%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

The Company’s presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, January 10, 2022, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse^® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts
LifeSci Advisors:
Brian Ritchie
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

When will Bellerophon present at the H.C. Wainwright BioConnect 2022 Conference?

Bellerophon will present at the conference on January 10, 2022.

What is the focus of Bellerophon Therapeutics?

Bellerophon Therapeutics focuses on developing treatments for cardiopulmonary diseases.

How can I access Bellerophon's presentation from the conference?

The presentation will be available on-demand on Bellerophon’s website starting January 10, 2022, at 7:00 AM Eastern Time.

What products does Bellerophon develop under its INOpulse program?

Bellerophon develops multiple product candidates under its INOpulse® program, which is a proprietary nitric oxide delivery system.

Is Bellerophon Therapeutics publicly traded?

Yes, Bellerophon Therapeutics is traded on Nasdaq under the ticker symbol BLPH.